The expanding population of patients with PD (37), the recognition that dementia is a very common non-motor complication of PD and the recent FDA approval of a cholinesterase inhibitor (rivastigmine) to treat PDD have created a surge of interest in recognising, diagnosing and treating PDD. The gene discussed is BCHE; the disease is Parkinson disease.